BioMarin shares climb on Shire takeover buzz

The M&A rumor mill was churning Friday morning on reports of an in-the-works Shire ($SHPG) deal for orphan drugmaker BioMarin Pharmaceuticals. According to Ben Harrington of the blog Betaville, Morgan Stanley and Lazard are advising the Dublin pharma on a buyout that could be worth $65 billion, and that helped spur UBS and Deutsche Bank to raise their BioMarin price targets. BioMarin shares shot up as much as 15% on the speculation, though as Citigroup pointed out in a note to investors, such a transaction remains deeply unlikely. Blog post | FierceBiotech story

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.